Korea's Samsung Electronics On Manhunt For Biosimilar Talent As Local Companies Keep Wary Eye On Competition
This article was originally published in The Pink Sheet Daily
Industry officials say about 10 biosimilar R&D experts from leading biopharmas have been recruited by Samsung, which sees the potential market for biosimilars and is moving beyond its traditional territory of electronics products.
You may also be interested in...
SEOUL - As part of its bid to stretch out for more global sales for a range of antibody therapeutic biosimilars, Celltrion has signed a deal with Perrigo to market its products in Israel
SEOUL - As the South Korean government accelerates its drive to get local producers of biosimilars globally competitive, the Ministry of Knowledge Economy is setting the stage for Samsung Electronics to become a giant in the emerging biosimlars market
Korean Celltrion Gears Up To Produce Biosimilar Herceptin, Remicade, Erbitux; Proposes Barter System In Developing Regions
SEOUL - "Celltrion is currently developing a total of nine blockbuster antibody therapeutic biosimilars, and we are preparing for the launch of three biosimilars for markets not protected with patent rights," Kim Yong-Joong, Celltrion's strategic planning assistant manager, told PharmAsia News